Customer BehaviorBiopharma customers have become more hesitant to make capital purchases of its systems, and this trend intensified.
Revenue GuidanceGuidance for non-SPL organic growth came in at 2%-9%, which at the midpoint is similar to large-cap bioprocessing peers but falls below more relevant comps like BioLife, Repligen, and Teknova.
Stock PerformanceShares are down 34% year-to-date reflecting broader market pressure on longer-duration assets, macro uncertainty, and its possible impact on MaxCyte’s customers.